Literature DB >> 16215709

[The role of PSA in diagnosis of prostate cancer and its recurrence].

D C Vergho1, K Heine, J M Wolff.   

Abstract

Prostate specific antigen is the most important tumor marker of prostate cancer. PSA, in conjunction with digital rectal examination, is the first-line clinical tool for detection of prostate cancer. To improve its specificity PSA-density, PSA-ratio (fPSA/tPSA), PSA-velocity, and complexed PSA have been introduced into clinical praxis. The treatment of lower stage disease in younger men has resulted in a longer period of post-treatment cancer surveillance. Biochemical recurrence is an early indicator for clinical disease recurrence. PSA doubling time allows to distinguish between local and systemic progression and is also a valid predictor for distant metastasis and death of disease.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16215709     DOI: 10.1007/s00292-005-0789-7

Source DB:  PubMed          Journal:  Pathologe        ISSN: 0172-8113            Impact factor:   1.011


  34 in total

1.  Ultrasensitive serum prostate specific antigen nadir accurately predicts the risk of early relapse after radical prostatectomy.

Authors:  Samson Shen; Herbert Lepor; Robert Yaffee; Samir S Taneja
Journal:  J Urol       Date:  2005-03       Impact factor: 7.450

2.  PSA and staging of localized prostate cancer.

Authors:  E Kleer; J E Oesterling
Journal:  Urol Clin North Am       Date:  1993-11       Impact factor: 2.241

3.  Prostate-specific antigen velocity and repeated measures of prostate-specific antigen.

Authors:  H B Carter; J D Pearson
Journal:  Urol Clin North Am       Date:  1997-05       Impact factor: 2.241

4.  Prostate-specific antigen as a serum marker for adenocarcinoma of the prostate.

Authors:  T A Stamey; N Yang; A R Hay; J E McNeal; F S Freiha; E Redwine
Journal:  N Engl J Med       Date:  1987-10-08       Impact factor: 91.245

5.  Use of the percentage of free prostate-specific antigen to enhance differentiation of prostate cancer from benign prostatic disease: a prospective multicenter clinical trial.

Authors:  W J Catalona; A W Partin; K M Slawin; M K Brawer; R C Flanigan; A Patel; J P Richie; J B deKernion; P C Walsh; P T Scardino; P H Lange; E N Subong; R E Parson; G H Gasior; K G Loveland; P C Southwick
Journal:  JAMA       Date:  1998-05-20       Impact factor: 56.272

Review 6.  [From antigen to tumor marker. Results of research regarding PSA and its clinical applications].

Authors:  G De Angelis; B Brandt; H P Schmid; A Semjonow
Journal:  Urologe A       Date:  2000-07       Impact factor: 0.639

Review 7.  Markers and meaning of primary treatment failure.

Authors:  Peter W Swindle; Michael W Kattan; Peter T Scardino
Journal:  Urol Clin North Am       Date:  2003-05       Impact factor: 2.241

8.  Variation of serum prostate-specific antigen levels: an evaluation of year-to-year fluctuations.

Authors:  James A Eastham; Elyn Riedel; Peter T Scardino; Moshe Shike; Martin Fleisher; Arthur Schatzkin; Elaine Lanza; Lianne Latkany; Colin B Begg
Journal:  JAMA       Date:  2003-05-28       Impact factor: 56.272

9.  Effect of finasteride on serum PSA concentration in men with benign prostatic hyperplasia. Results from the North American phase III clinical trial.

Authors:  H A Guess; J F Heyse; G J Gormley; E Stoner; J E Oesterling
Journal:  Urol Clin North Am       Date:  1993-11       Impact factor: 2.241

Review 10.  Dihydrotestosterone and the prostate: the scientific rationale for 5alpha-reductase inhibitors in the treatment of benign prostatic hyperplasia.

Authors:  Gerald Andriole; Nicholas Bruchovsky; Leland W K Chung; Alvin M Matsumoto; Roger Rittmaster; Claus Roehrborn; David Russell; Donald Tindall
Journal:  J Urol       Date:  2004-10       Impact factor: 7.450

View more
  3 in total

1.  Low serum testosterone levels are predictive of prostate cancer.

Authors:  Luigi Mearini; Alessandro Zucchi; Elisabetta Nunzi; Tommaso Villirillo; Vittorio Bini; Massimo Porena
Journal:  World J Urol       Date:  2011-11-09       Impact factor: 4.226

2.  Is a decreased serum testosterone level a risk factor for prostate cancer? A cohort study of korean men.

Authors:  Bo Sung Shin; Eu Chang Hwang; Chang Min Im; Sun-Ouck Kim; Seung Il Jung; Taek Won Kang; Dong Deuk Kwon; Kwangsung Park; Soo Bang Ryu
Journal:  Korean J Urol       Date:  2010-12-21

Review 3.  Graphene-based biosensors for the detection of prostate cancer protein biomarkers: a review.

Authors:  Li Xu; Yanli Wen; Santosh Pandit; Venkata R S S Mokkapati; Ivan Mijakovic; Yan Li; Min Ding; Shuzhen Ren; Wen Li; Gang Liu
Journal:  BMC Chem       Date:  2019-09-03
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.